CN1324013C - 芳基稠合氮杂多环化合物 - Google Patents

芳基稠合氮杂多环化合物 Download PDF

Info

Publication number
CN1324013C
CN1324013C CNB988128195A CN98812819A CN1324013C CN 1324013 C CN1324013 C CN 1324013C CN B988128195 A CNB988128195 A CN B988128195A CN 98812819 A CN98812819 A CN 98812819A CN 1324013 C CN1324013 C CN 1324013C
Authority
CN
China
Prior art keywords
alkyl
compound
disease
ring
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988128195A
Other languages
English (en)
Chinese (zh)
Other versions
CN1285821A (zh
Inventor
乔瑟姆·W·科
佩奇·R·P·布鲁克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1324013(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1285821A publication Critical patent/CN1285821A/zh
Application granted granted Critical
Publication of CN1324013C publication Critical patent/CN1324013C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB988128195A 1997-12-31 1998-11-13 芳基稠合氮杂多环化合物 Expired - Lifetime CN1324013C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7024597P 1997-12-31 1997-12-31
US60/070,245 1997-12-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2005100821428A Division CN1715280A (zh) 1997-12-31 1998-11-13 芳基稠合氮杂多环化合物

Publications (2)

Publication Number Publication Date
CN1285821A CN1285821A (zh) 2001-02-28
CN1324013C true CN1324013C (zh) 2007-07-04

Family

ID=22094096

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988128195A Expired - Lifetime CN1324013C (zh) 1997-12-31 1998-11-13 芳基稠合氮杂多环化合物
CNA2005100821428A Pending CN1715280A (zh) 1997-12-31 1998-11-13 芳基稠合氮杂多环化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2005100821428A Pending CN1715280A (zh) 1997-12-31 1998-11-13 芳基稠合氮杂多环化合物

Country Status (51)

Country Link
US (6) US6410550B1 (https=)
EP (2) EP1044189B2 (https=)
JP (1) JP3550359B2 (https=)
KR (1) KR100408138B1 (https=)
CN (2) CN1324013C (https=)
AP (1) AP1170A (https=)
AR (1) AR017967A1 (https=)
AT (1) ATE386024T1 (https=)
AU (1) AU753389C (https=)
BG (1) BG65058B1 (https=)
BR (2) BR9814592B1 (https=)
CA (1) CA2316921C (https=)
CO (1) CO4810373A1 (https=)
CY (2) CY1107391T1 (https=)
CZ (1) CZ301925B6 (https=)
DE (2) DE69839131T3 (https=)
DK (1) DK1044189T4 (https=)
DZ (1) DZ2697A1 (https=)
EA (1) EA003190B1 (https=)
EG (1) EG23816A (https=)
ES (1) ES2301210T5 (https=)
FR (1) FR08C0039I2 (https=)
GT (2) GT199800200A (https=)
HN (1) HN1998000177A (https=)
HR (2) HRP20050506A2 (https=)
HU (2) HU230297B1 (https=)
IL (2) IL136727A0 (https=)
IS (1) IS5514A (https=)
LU (1) LU91442I2 (https=)
MA (1) MA26589A1 (https=)
ME (1) ME00459B (https=)
MY (1) MY118163A (https=)
NL (1) NL300355I2 (https=)
NO (2) NO319115B1 (https=)
NZ (1) NZ504482A (https=)
OA (1) OA11428A (https=)
PA (1) PA8463901A1 (https=)
PE (1) PE20000053A1 (https=)
PL (1) PL209404B1 (https=)
PT (1) PT1044189E (https=)
RS (1) RS50069B (https=)
SA (1) SA99191123B1 (https=)
SG (1) SG102686A1 (https=)
SI (1) SI1044189T2 (https=)
SK (1) SK286886B6 (https=)
TN (1) TNSN98237A1 (https=)
TR (1) TR200001840T2 (https=)
TW (1) TW513412B (https=)
UA (1) UA66825C2 (https=)
WO (1) WO1999035131A1 (https=)
ZA (1) ZA9811911B (https=)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50069B (sr) * 1997-12-31 2009-01-22 Pfizer Products Inc., Aril kondenzovana azapoliciklična jedinjenja
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
ES2313900T3 (es) 1999-07-28 2009-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nicotina en angiogenesis y vasculogenesis terapeutica.
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
WO2002085843A2 (en) 2001-04-20 2002-10-31 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
EE200300557A (et) * 2001-05-14 2004-04-15 Pfizer Products Inc. 5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool
GEP20053712B (en) * 2001-05-14 2005-12-26 Pfizer Prod Inc Tartrate Salts of 5,8,14-Triazatetracyclo {10.3.1.0²,11.04,9}-Hexadeca-2(11),3,5,7,9-Pentaene and Pharmaceutical Compositions Thereof
EP1461040B1 (en) * 2001-11-29 2006-03-15 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
CN1596263A (zh) 2001-11-30 2005-03-16 辉瑞产品公司 芳基－稠合的氮杂多环化合物
WO2003045437A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
AU2003215272B2 (en) 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7776545B2 (en) * 2002-11-20 2010-08-17 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for Celiac Sprue
AU2003234634A1 (en) * 2002-05-14 2003-12-02 Felix Hausch Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
MXPA05005366A (es) 2002-11-20 2005-08-03 Pfizer Prod Inc Un metodo para preparar acido indano-1,3-dicarboxilico.
WO2004048318A1 (en) * 2002-11-25 2004-06-10 Pfizer Products Inc. Improved process for the preparation of 1,3-substituted indenes
BRPI0406670A (pt) * 2003-01-15 2005-12-20 Pfizer Prod Inc Processo para a preparação de lactamas policìclicas fundidos com arila
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
WO2004108725A1 (en) * 2003-06-04 2004-12-16 Pfizer Products Inc. Preparation of substituted quinoxalines from the dianline with 2,3-dihydroxy-1,4-dioxane
CA2533100A1 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds
ES2331245T3 (es) * 2003-07-21 2009-12-28 Pfizer Products Inc. Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina.
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
US7766018B2 (en) * 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
MX2007010375A (es) * 2005-02-24 2007-09-25 Pfizer Prod Inc Preparacion de quinoxalina sustituida de elevada pureza.
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
RU2008138532A (ru) * 2006-03-27 2010-04-10 Пфайзер Продактс Инк. (Us) Стандарты варениклина и контроль примесей
CN101420939A (zh) * 2006-04-24 2009-04-29 辉瑞产品公司 用于药物递送装置的不对称膜
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
EP2086977A2 (en) * 2006-11-09 2009-08-12 Pfizer Products Inc. Polymorphs of nicotinic intermediates
WO2008115411A1 (en) * 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009101185A2 (en) * 2008-02-15 2009-08-20 Medichem, S.A. A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
WO2009146031A1 (en) 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8039620B2 (en) 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
EP2204369A1 (en) 2008-12-22 2010-07-07 Medichem, S.A. Process for preparing varenicline and intermediates for use therein
BRPI1008020A2 (pt) 2009-02-11 2016-03-15 Sunovion Pharmaceuticals Inc antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos
WO2010143070A2 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en) 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
MX2012002898A (es) * 2009-09-11 2012-04-02 Sunovion Pharmaceuticals Inc Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos.
EP2545054A1 (en) 2010-03-09 2013-01-16 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
KR101109389B1 (ko) * 2010-04-30 2012-01-30 삼성전기주식회사 인쇄회로기판 및 그 제조방법
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
BR112013032044A2 (pt) 2011-06-30 2016-12-13 Toray Industries antiprurítico
ITMI20111413A1 (it) 2011-07-28 2013-01-29 Dipharma Francis Srl Procedimento per la preparazione di vareniclina
ES2426517B1 (es) 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
ES2426838B1 (es) 2012-04-20 2014-05-07 Genetracer Biotech S.L Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico
CN103570502A (zh) * 2012-07-18 2014-02-12 上海科胜药物研发有限公司 一种伐伦克林中间体的制备方法
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN103992272B (zh) * 2014-06-09 2016-05-11 安徽省逸欣铭医药科技有限公司 一种盐酸喷他佐辛酯、其制备方法及其用途
KR20160126697A (ko) 2015-04-24 2016-11-02 한미정밀화학주식회사 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20160143407A (ko) 2015-06-05 2016-12-14 한미정밀화학주식회사 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
CN106674194B (zh) * 2016-12-14 2019-03-05 山东省联合农药工业有限公司 一种结构新颖的烟碱类杀虫剂及其制备方法和用途
EP3590498A4 (en) 2017-03-03 2020-12-16 CTC Bio, Inc. PREPARATION, INCLUDING AN INCLUSION COMPLEX OF VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREFOR, FOR ORAL ADMINISTRATION
KR102463733B1 (ko) 2017-06-30 2022-11-04 한미약품 주식회사 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
WO2021092275A1 (en) 2019-11-06 2021-05-14 Children’S National Medical Center Methods and compositions for the prevention and treatment of ischemia reperfusion injury and infection
ES3039903T3 (en) 2020-04-28 2025-10-27 Oyster Point Pharma Inc Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
US11040983B1 (en) 2020-08-14 2021-06-22 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022035434A1 (en) 2020-08-14 2022-02-17 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (en) * 2020-12-30 2022-07-07 Antares Pharma, Inc. Varenicline prodrugs
WO2022222019A1 (en) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Total synthesis of varenicline
CN113277993B (zh) * 2021-06-06 2023-07-21 湖南第一师范学院 一种Tafamidis及其衍生物的合成方法
EP4452236A2 (en) 2021-12-23 2024-10-30 Medichem, S.A. Solid pharmaceutical formulations of varenicline
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2024095172A1 (en) 2022-11-04 2024-05-10 Pfizer Inc. Prodrugs of varenicline and compounds containing vulnerable amines
IT202300003888A1 (it) 2023-03-03 2024-09-03 Dipharma Francis Srl Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina
WO2024224270A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Varenicline formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) * 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
JPH11512443A (ja) † 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
RS50069B (sr) * 1997-12-31 2009-01-22 Pfizer Products Inc., Aril kondenzovana azapoliciklična jedinjenja
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
WO1999042461A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
WO1999055680A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds
ES2305373T3 (es) * 1999-01-29 2008-11-01 Abbott Laboratories Derivados diazabiciclicos como ligandos del receptor nicotinico de la acetilcolina.
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
GEP20053712B (en) * 2001-05-14 2005-12-26 Pfizer Prod Inc Tartrate Salts of 5,8,14-Triazatetracyclo {10.3.1.0²,11.04,9}-Hexadeca-2(11),3,5,7,9-Pentaene and Pharmaceutical Compositions Thereof
EE200300557A (et) * 2001-05-14 2004-04-15 Pfizer Products Inc. 5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool
EP1461040B1 (en) * 2001-11-29 2006-03-15 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
CN1596263A (zh) * 2001-11-30 2005-03-16 辉瑞产品公司 芳基－稠合的氮杂多环化合物
WO2003045437A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
CA2533100A1 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) * 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols

Also Published As

Publication number Publication date
TW513412B (en) 2002-12-11
DK1044189T3 (da) 2008-05-13
DK1044189T4 (en) 2015-03-30
US20070275973A1 (en) 2007-11-29
HRP20050506A2 (en) 2006-03-31
EP1044189B2 (en) 2015-02-25
BR9814592A (pt) 2000-10-17
US6887884B2 (en) 2005-05-03
US20020072525A1 (en) 2002-06-13
NO319115B1 (no) 2005-06-20
CZ20002438A3 (cs) 2002-11-13
HK1031878A1 (en) 2001-06-29
BR9816186B1 (pt) 2009-01-13
PT1044189E (pt) 2008-04-22
SI1044189T1 (sl) 2008-06-30
BR9814592B1 (pt) 2010-06-01
ES2301210T3 (es) 2008-06-16
ES2301210T5 (es) 2015-05-07
UA66825C2 (uk) 2004-06-15
JP3550359B2 (ja) 2004-08-04
CY2008013I1 (el) 2009-11-04
US20020132824A1 (en) 2002-09-19
PL209404B1 (pl) 2011-08-31
KR100408138B1 (ko) 2003-12-01
CY1107391T1 (el) 2010-07-28
SI1044189T2 (sl) 2015-05-29
NL300355I2 (nl) 2008-11-03
NO2006016I2 (https=) 2008-10-20
HRP20000445B1 (hr) 2009-04-30
MA26589A1 (fr) 2004-12-20
EA200000592A1 (ru) 2000-12-25
EP1044189B1 (en) 2008-02-13
EG23816A (en) 2007-09-19
PA8463901A1 (es) 2000-09-29
AP9801422A0 (en) 1998-12-31
HUS1600018I1 (hu) 2018-05-02
HU230297B1 (hu) 2015-12-28
DE69839131D1 (de) 2008-03-27
EP1659114A2 (en) 2006-05-24
CY2008013I2 (el) 2009-11-04
PE20000053A1 (es) 2000-02-07
WO1999035131A1 (en) 1999-07-15
LU91442I2 (fr) 2008-07-21
KR20010033823A (ko) 2001-04-25
SA99191123B1 (ar) 2006-10-02
ZA9811911B (en) 2000-06-29
AU9641698A (en) 1999-07-26
TNSN98237A1 (fr) 2005-03-15
AU753389C (en) 2007-08-09
EP1044189A1 (en) 2000-10-18
IL136727A0 (en) 2001-06-14
IS5514A (is) 2000-05-26
DE69839131T3 (de) 2015-05-07
BG65058B1 (bg) 2007-01-31
NL300355I1 (nl) 2008-08-01
GT199800200AA (es) 2000-06-07
DE69839131T2 (de) 2009-02-05
US6897310B2 (en) 2005-05-24
CN1715280A (zh) 2006-01-04
SK286886B6 (sk) 2009-07-06
HUP0100949A3 (en) 2002-12-28
EP1659114A3 (en) 2007-01-17
FR08C0039I1 (https=) 2008-11-14
YU40300A (sh) 2003-10-31
SG102686A1 (en) 2004-03-26
US6951938B2 (en) 2005-10-04
HN1998000177A (es) 1999-02-09
IL136727A (en) 2006-06-11
CA2316921C (en) 2004-12-07
AU753389B2 (en) 2002-10-17
RS50069B (sr) 2009-01-22
CN1285821A (zh) 2001-02-28
HRP20000445A2 (en) 2001-04-30
HUP0100949A2 (hu) 2001-08-28
NO20003422D0 (no) 2000-06-30
NZ504482A (en) 2003-01-31
EA003190B1 (ru) 2003-02-27
SK9712000A3 (en) 2002-03-05
PL341824A1 (en) 2001-05-07
CZ301925B6 (cs) 2010-08-04
ME00459B (me) 2011-10-10
US20020111350A1 (en) 2002-08-15
AR017967A1 (es) 2001-10-24
NO2006016I1 (no) 2006-11-27
CA2316921A1 (en) 1999-07-15
TR200001840T2 (tr) 2000-12-21
JP2002500218A (ja) 2002-01-08
DZ2697A1 (fr) 2003-03-29
US6410550B1 (en) 2002-06-25
BG104561A (en) 2001-01-31
CO4810373A1 (es) 1999-06-30
AP1170A (en) 2003-06-30
GT199800200A (es) 2000-06-07
DE122008000038I1 (de) 2008-11-13
FR08C0039I2 (fr) 2009-12-18
MY118163A (en) 2004-09-30
NO20003422L (no) 2000-08-29
OA11428A (en) 2004-05-03
US20020072524A1 (en) 2002-06-13
ATE386024T1 (de) 2008-03-15
LU91442I9 (https=) 2018-12-31

Similar Documents

Publication Publication Date Title
CN1324013C (zh) 芳基稠合氮杂多环化合物
CN1263745C (zh) 芳基稠合的氮杂多环化合物
CN1289499C (zh) 吡嗪并(氮杂)吲哚衍生物
CN1620455A (zh) 作为5－羟色胺－6配体的氮杂吲哚基烷基胺衍生物
CN1072219C (zh) 二氮杂䓬酮、其生产和用途
CN1823068A (zh) 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物
CN1950371A (zh) 用作组胺h3受体配体的四氢萘啶衍生物
CN1067655A (zh) 含氮杂环类化合物的氟代烷氧基苄氨基衍生物
CN1556702A (zh) 具有作为激酶抑制剂的活性的氨基吲唑衍生物、它们的制备方法和含有它们的药物组合物
CN1489581A (zh) 喹唑啉酮衍生物
CN1703403A (zh) 趋代谢的谷氨酸盐受体拮抗剂
CN1361779A (zh) 新化合物
CN1059143A (zh) 吡唑并吡啶化合物及其制备方法
CN1503781A (zh) 1,3-取代的茚类和芳基稠合的氮杂多环化合物的制备方法
CN1352644A (zh) 抑制磷酸二酯酶IV的1－氨基三唑并[4,3－α]喹唑啉－5酮类化合物和/或－5－硫酮类化合物
CN1229375C (zh) 烟碱型乙酰胆碱受体抑制剂化合物、其制备和应用
CN1802187A (zh) 趋化因子受体的苯并噁嗪基－酰胺基环戊基－杂环调节剂
CN1144787C (zh) 芳基稠合氮杂多元环化合物
CN1499972A (zh) 用作促肾上腺皮质激素释放因子抑制剂的咪唑基衍生物
CN1129578C (zh) 四氢苯并吲哚衍生物
CN1599737A (zh) 稠环吡唑衍生物
CN1856495A (zh) 作为诱导型no－合酶抑制剂的咪唑并吡啶类衍生物
CN1066071A (zh) 6-杂环基-4-氨基-1，2，2a，3，4，5-六氢苯并[cd]吲哚
CN1856493A (zh) 氨基吡啶衍生物作为可诱导的no－合酶抑制剂
CN1164856A (zh) 作为σ2选择性配体的新的烷基氨基衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070704